Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - iopromide - solution for injection - 300 milligram(s)/millilitre - watersoluble, nephrotropic, low osmolar x-ray contrast media; iopromide

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - iopromide - solution for injection - 370 milligram(s)/millilitre - watersoluble, nephrotropic, low osmolar x-ray contrast media; iopromide

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - ultravist® injection is an iodinated contrast agent indicated for: ultravist is indicated for: ultravist is indicated for: † specific concentrations and presentations of ultravist are recommended for each type of imaging procedure [see dosage and administration ( 2.2, 2.3, 2.4)]. there are no data on ultravist use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data) . in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other advers

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - iopromide - solution for injection - 240 milligram(s)/millilitre - watersoluble, nephrotropic, low osmolar x-ray contrast media; iopromide

Malta - English - Medicines Authority

bayer hellas s.a 6-8 agisilaou street 151 23 marousi attiki, , greece - iodine - solution for injection - iodine 768,86 mg/ml - contrast media

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - iodine 240 mg in 1 ml - ultravist® injection is an iodinated contrast agent indicated for: *for information on the concentrations and doses for the pediatric population [see dosage and administration (2.3) and use in specific populations (8.4)]. risk summary there are no data on ultravist injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to 0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data). . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general p

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - ultravist® injection is an iodinated contrast agent indicated in adults pediatric patients for use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this imaging bulk package. risk summary there are no data on ultravist injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to 0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data). . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of

Canada - English - Health Canada

bayer inc - iopromide - solution - 50% - iopromide 50% - roentgenography

Canada - English - Health Canada

bayer inc - iopromide - solution - 62% - iopromide 62% - roentgenography

Canada - English - Health Canada

bayer inc - iopromide - solution - 77% - iopromide 77% - roentgenography